Target type: biologicalprocess
The process in which angiotensinogen metabolites in the bloodstream modulate the force with which blood passes through the circulatory system. The process begins when renin is released and cleaves angiotensinogen. [ISBN:0721643949]
The renin-angiotensin system (RAS) plays a crucial role in regulating systemic arterial blood pressure. This complex system involves a cascade of enzymatic reactions that ultimately lead to the production of angiotensin II, a potent vasoconstrictor.
The process begins in the kidneys, specifically in the juxtaglomerular cells located near the glomeruli. These cells sense changes in blood pressure, sodium levels, and blood flow. When blood pressure drops, the juxtaglomerular cells release renin, an enzyme that converts angiotensinogen, a protein produced in the liver, into angiotensin I.
Angiotensin I then travels through the bloodstream and reaches the lungs, where it encounters angiotensin-converting enzyme (ACE). ACE, an enzyme found primarily in the lungs, converts angiotensin I into angiotensin II.
Angiotensin II acts as a powerful vasoconstrictor, causing blood vessels to narrow, thereby increasing peripheral resistance and blood pressure. It also stimulates the release of aldosterone from the adrenal glands, a hormone that promotes sodium retention by the kidneys, further contributing to increased blood volume and blood pressure.
In addition to its direct effects on blood pressure, angiotensin II also activates various signaling pathways that affect other organs, including the heart, brain, and kidneys. It can cause hypertrophy (enlargement) of the heart, promote atherosclerosis (hardening of the arteries), and contribute to the development of kidney disease.
The RAS is finely regulated by various feedback mechanisms. For example, increased blood pressure inhibits the release of renin from the kidneys, reducing the production of angiotensin II. Additionally, angiotensin II itself can inhibit its own production by suppressing renin release and downregulating ACE expression.
The regulation of systemic arterial blood pressure by the RAS is essential for maintaining cardiovascular homeostasis. Disruptions to this system, such as overactivation of the RAS, can lead to hypertension (high blood pressure) and other cardiovascular diseases. Therefore, understanding the complex mechanisms involved in RAS regulation is crucial for developing effective treatments for these conditions.'
"
Protein | Definition | Taxonomy |
---|---|---|
Type-2 angiotensin II receptor | An angiotensin II receptor 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P50052] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
5-iodo-2-(oxaloamino)benzoic acid | organoiodine compound | ||
candesartan | candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension. candesartan: a nonpeptide angiotensin II receptor antagonist | benzimidazolecarboxylic acid; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
avapro | irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. | azaspiro compound; biphenylyltetrazole | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
losartan | losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. | biphenylyltetrazole; imidazoles | angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist |
miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
ipsapirone | N-arylpiperazine | ||
flesinoxan | |||
valsartan | valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity. Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION. | biphenylyltetrazole; monocarboxylic acid; monocarboxylic acid amide | angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic |
telmisartan | telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension. Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION. | benzimidazoles; biphenyls; carboxybiphenyl | angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic |
bexarotene | benzoic acids; naphthalenes; retinoid | antineoplastic agent | |
exp7711 | EXP7711: to search, use E#P7711(nm); angiotensin II receptor antagonist; structure given in first source | ||
bibs 39 | BIBS 39: structure given in first source; angiotensin II receptor antagonist | ||
a 81988 | A 81988: angiotensin II antagonist selective for type 1 receptors | ||
bibs 222 | BIBS 222: structure given in first source; angiotensin II receptor antagonist | ||
chrysamine g | chrysamine G: structure given in first source; RN refers to disodium salt | ||
angiotensin ii | Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V). | amino acid zwitterion; angiotensin II | human metabolite |
l 158809 | L 158809: RN & structure given in first source; angiotensin receptor antagonist | ||
2-(oxaloamino)benzoic acid | (oxaloamino)benzoic acid | ||
alitretinoin | Alitretinoin: A retinoid that is used for the treatment of chronic hand ECZEMA unresponsive to topical CORTICOSTEROIDS. It is also used to treat cutaneous lesions associated with AIDS-related KAPOSI SARCOMA. | retinoic acid | antineoplastic agent; keratolytic drug; metabolite; retinoid X receptor agonist |
tak 013 | |||
pd 123319 | PD123319 : An imidazopyridine consisting of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine having 4-(dimethylamino)-3-methylbenzyl, diphenylacetyl and carboxy and groups at positions 1, 5 and 6 respectively | imidazopyridine | angiotensin receptor antagonist; endothelin receptor antagonist; vasoconstrictor agent |
exp 655 | |||
saralasin | Saralasin: An octapeptide analog of angiotensin II (bovine) with amino acids 1 and 8 replaced with sarcosine and alanine, respectively. It is a highly specific competitive inhibitor of angiotensin II that is used in the diagnosis of HYPERTENSION. | oligopeptide | |
l 162313 | L 162313: a biphenylimidazole derivative; a non-peptide angiotensin agonist; no further information available 2/95 | ||
l 163491 | L 163491: structure given in first source | ||
nrx 194204 | IRX4204: retinoid X receptor (RXR) agonist; structure in first source | ||
agn 194204 | AGN 194204: a retinoid X receptor ligand; structure in first source | ||
ema401 | |||
naluzotan | naluzotan: an antidepressant and anti-anxiety agent; structure in first source |